Expand Your

IV Formulation Options

3 New Sterile Products,

from Your New 503B Partner

At Willowbend Pharma we are excited and committed to supporting your practice with cGMP quality, consistent sterile compounded medications prepared for provider-directed office use through our FDA registered 503B outsourcing facility.

Connect with your regional representative to learn more about our launch portfolio and upcoming products.

NEW STERILE IV INGREDIENTS

Introducing Our Launch Portfolio

Our launch portfolio is the first step in our commitment to expanding sterile compounded medication options.

As Willowbend Pharma continues to grow, additional products and expanded availability are planned.

Available Strengths

NIAGEN® IV

Sterile Nicotinamide Riboside

Chloride for Injection

Designed for provider-directed IV protocols with E-Beam sterilized, preservative-free powder prior to reconstitution.

Biotin Injection

Sterile Compounded Biotin

for Injection

A 10 mg/mL sterile injectable formulation designed for incorporation into provider-directed IV therapy and individualized wellness protocols.

Ascorbic Acid Injection

Sterile Compounded Vitamin C

for Injection

A 500 mg/mL sterile ascorbic acid formulation offering flexibility for individualized IV protocols and wellness regimens.

BUILT TO SUPPORT PROVIDERS

Meet Willowbend Pharma

Willowbend is actively expanding its sterile compounded portfolio with additional injectable vitamins, hormone therapies, and other office-use sterile medications designed to support evolving provider needs.

FDA-Registered 503B

Outsourcing Facility

Quality-Focused

Manufacturing

Growing Sterile

Portfolio

Dedicated Provider

Support

Expanding State

Licensure

Rapid Inquiry

Response

Ready to Learn More?
Start the Conversation.
Complete the form below and a Willowbend representative will contact you to discuss your practice, answer questions, and explore how our growing sterile portfolio can support your needs.

Disclaimer: Compounded preparations are not reviewed by the FDA for safety or efficacy. Products from 503B outsourcing facilities are compounded in

accordance with section 503B of the Federal Food, Drug, and Cosmetic Act and are intended for office use only as directed by a licensed healthcare professional.

© 2026. All Rights Reserved. Willowbend Pharma Select.